International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1834-1844 www.ijprajournal.com ISSN: 2456-4494

Diabetes Mellitus: A Comprehensive Review of pathophysiology, Diagnosis and management.

Akshata.R.Sathe*, Sucheta.S.Pawar, Pratiksha.S. Khamkar, Shreya. A.Kirdat, Vipassana.V.Khandait

**Student, YSPM,YTC, Yashoda Technical Campus, Satara,Maharashtra.*

Date of Submission: 15-04-2025 Date of Acceptance: 25-04-2025

ABSTRACT:-
One of the most prevalent non-communicable diseases in the world is "diabetes mellitus." India confronts a number of difficulties in managing diabetes, such as an increase in both urban and rural incidence, a lack of public awareness of the condition, a shortage of medical facilities, high treatment costs, inadequate glycaemic control, and an increase in diabetic complications. The most popular method of administering insulin therapy for diabetes is subcutaneous injections, which can occur up to four times daily. The intrusive aspect of long-term insulin therapy has led to issues with patient compliance, which has eventually affected patient outcomes. Although type 1 diabetes is becoming increasingly common, type 2 diabetes mellitus, which causes more than 90% of all cases of diabetes, is the primary cause of the diabetic epidemic. In addition to other risk factors including obesity and a sedentary lifestyle, type 2 diabetes is a serious and prevalent chronic illness that is caused by a complex interaction between inheritance and environment.

KEYWORDS :- Introduction, Classification, epidemiology, pathophysiology, causes, diagnosis, Management, insulin therapy, hypoglycemic agent, herbal treatment, conclusion, acknowledgement.

I. INTRODUCTION :-

Definition of Diabetes Mellitus :-

Chronic hyperglycemia is a metabolic disease brought on by either insufficient insulin secretion, ineffective insulin action, or both. A noteworthy anabolic hormone that influences the metabolism of proteins, fats, and carbohydrates is insulin [1].

Over 100 million people globally (6% of the population) suffer with diabetes mellitus (DM), the most prevalent endocrine condition. It is brought on by insufficient or inefficient insulin production by the pancreas, which causes blood glucose levels to rise or fall. Numerous bodily systems, including the heart, kidney, blood vessels, eyes, and nerves, are shown to be harmed by it[2].Adipose tissue, skeletal muscles, and the liver are the primary tissues affected by the metabolic problems linked to diabetes because of insulin resistance. Depending on the kind and length of diabetes, the intensity of symptoms can change.People who have high blood sugar levels, especially children who don't have any insulin at all, may have symptoms like weight loss, increased appetite, polydipsia, dysuria, and visual issues. Some diabetics, particularly those with type 2 diabetes in its early stages, may not exhibit any symptoms[3]. The pancreas secretes the hormones insulin and glucagon. The beta (ß) cells in the islets of Langerhans secrete insulin, while the alpha (α) cells secrete glucagon each. By promoting glycogenesis, insulin lowers blood glucose levels and transfers glucose to the muscles, liver, and adipose tissue. Neural tissue and erythrocytes may use glucose without insulin, but alpha (α) cells are crucial for blood glucose regulation because they produce glucagon, which raises blood glucose levels by speeding up glycogenolysis [4,5].The WHO reported in 2014 that 8.5% of adults over the age of 18 had diabetes. 48% of the 1.5 million fatalities from diabetes that occurred in 2019 happened in those under the age of 70. Furthermore, diabetes contributed to an additional 460,000 fatalities from kidney disease, and high blood glucose levels were linked to almost 20% of deaths from cardiovascular disease. Standardised death rates from diabetes increased by 3% between 2000 and 2019. The death rate linked to diabetes rose by 13% in lower-middle-income nations.On the other hand, between 2000 and 2019, the chance of dying from any of the four main non-communicable diseaseswhich include diabetes, cancer,chronic respiratory conditions, or cardiovascular diseasesamong those aged 30 to 70 decreased by 22% globally[6].

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1834-1844 www.ijprajournal.com ISSN: 2456-4494

CLASSIFICATION OF DIABETES MELLITUS :-

The World Health Organisation produced the first widely recognised categorisation of diabetes mellitus in 1980 [7], and it was updated in 1985 [8]. We'll talk about primary or idiopathic diabetes mellitus, which is the most prevalent and significant type. It must be distinct from secondary diabetes mellitus, which encompasses types of hyperglycemia linked to recognizable causes, such as inflammatory pancreatic diseases, surgery, tumors, specific medications, iron overload (hemochromatosis), and specific acquired or genetic endocrinopathies [9].

1.Type 1 DM :-(insulin dependent diabetes mellitus)

Type 1 diabetes mellitus waspreviously referred to as juvenile-onset or ketosis-prone diabetes, this kind of diabetes mellitus is also known as autoimmune diabetes. The patient may also seek treatment for further autoimmune conditions like Addison's disease, Hashimoto's thyroiditis, and Graves' disease [10] .Type I diabetes mellitus, commonly referred to as insulin-dependent diabetes mellitus (IDDM), primarily affects children and young adults. It typically develops suddenly and can be fatal [11]. Insulin-secreting cells are selectively destroyed after a local inflammatory response in and around the islets characterizes type I diabetes, an autoimmune illness [12]. It is possible to identify type 1 diabetes (T1D) well before aberrant insulin secretion begins, and the condition steadily declines for at least two years prior to diagnosis [13].

• Idiopathic type 1 diabetes mellitus :-

There have been reports of a rare form of T1D called "idiopathic diabetes," which is less severe than autoimmune T1D and not brought on by autoimmunity. Insulin insufficiency and episodic ketoacidosis are possible symptoms of idiopathic diabetes. Those with Asian or African ancestry are more likely to have this variation [14].

• Fulminant type 1 diabetes mellitus :-

This particular type of T1D was first recognized in 2000. It is not immune-mediated, which is one of its shared traits with idiopathic T1D [15]. Serum C-peptide levels, a sign of the endogenous production of insulin, are undetectable when blood glucose levels are high (288 mg/dL), and ketoacidosis develops soon after hyperglycemia begins. Acute-onset T1D, which has primarily been described in East Asian countries, affects about 20% of Japanese individuals (5000–7000 cases). It results in nearly total and extremely rapid β-cell death, leaving virtually no insulin production left behind. The primary causes of this illness are thought to be genetic and environmental. An antiviral immune response may result in the death of pancreatic β-cells by boosting the immune system without clearly forming autoantibodies that target the cells. Pregnancy and this kind of diabetes have also been reported [16].

2.Type 2 DM :-(Non insulin dependent diabetes mellitus)

Insulin resistance (IR) and metabolic syndrome (MS) are often present in type 2 diabetes (T2D), which is defined by a nonautoimmune, heterogeneously increasing lack of sufficient islet β cell insulin production. We use the term "metabolic dysfunction syndrome (MDS)" in place of MS because we believe that "metabolic" or "metabolism" describes physiological events that cannot be distinguished as normal or dysfunctional. 96% of diabetes is caused by type 2 diabetes, which is one of the major chronic noncommunicable diseases that pose a major danger to human health but whose etiology is not fully understood. Prolonged hyperglycemia can cause target organ damage (TOD) by raising the risk of atherosclerotic macrovascular disease (cardiovascular, cerebrovascular, and other peripheral vascular diseases) and microvascular disease (diabetic retinopathy, nephropathy, and neuropathy). T2D is only one component of MDS, whereas classical T1D primarily consists of hyperglycemia. It is frequently accompanied by other components of MDS, such as dyslipidemia, metabolic dysfunction associated steatotic liver disease (MASLD), overweight/obesity (preobesity may be a better term than "overweight" since obesity is not solely based on weight), and overweight. They typically fall within the category of T2D's upstream illnesses.[17]

3. Gestational Diabetes Mellitus :-

Gestational diabetes mellitus (GDM) is the term used to describe glucose intolerance that develops or is initially identified during pregnancy [18].Gestational diabetes mellitus (GDM) is the term used to describe women who acquire Type 1 diabetes mellitus during pregnancy as well as those who have undetected asymptomatic Type 2 diabetes mellitus that is identified during pregnancy [19].GDM, or gestational diabetes mellitus, is a

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1834-1844 www.ijprajournal.com ISSN: 2456-4494

type of pregnancy-related diabetes that is not obviously associated with diabetes [20]. The main cause of the higher prevalence of pregnancy-related issues, including preterm birth, large-for-gestational-age births, macrosomia (birth weight > 4.5 kg), cesarean delivery, and preeclampsia, is pregnancy-related hyperglycemia, which results in larger neonates. Numerous risk factors, including a family history of the condition, obesity, advanced maternal age, polycystic ovarian syndrome, a sedentary lifestyle, and exposure to environmental contaminants, can have an impact on gestational diabetes [21].

4. Other specific types of Diabetes Mellitus :-

Genetic defects of the beta-cell :-

Young people with maturity-onset diabetes (MODY): This kind of diabetes is linked to aberrant monogenetic β-cell activity. It is characterized by decreased insulin secretion and little to no anomalies in insulin action, and it usually manifests early, usually before the age of 25. Because the disorder is inherited in an autosomal dominant fashion, it can be brought on by just one copy of the faulty gene from either parent. MODY has been linked to mutations in a number of genes, including hepatic transcription factor (HNF)-1, glucokinase, HNF-4, HNF-1α, IPF-1, and NeuroD1 [22].

Genetic defects in insulin action :-

Insulin receptor gene mutations: Anomalies in insulin function may result from specific gene mutations of insulin receptors. These insulin-related mutations can result in a range of metabolic disorders, from mildly raised blood sugar and higher insulin levels to severe diabetes. Other symptoms including acanthosis nigricans (darkening of the skin), virilization (growth of male traits), and larger cystic ovaries in women are occasionally seen in people with these genes. Mild or even normal glucose metabolism may result from these molecules' poor binding to the insulin receptor, even in the presence of mutant insulin [23].

Diseases of the exocrine pancreas :-

Diabetes can result from a number of illnesses that cause extensive pancreatic damage. Pancreatectomy (surgical removal of the pancreas), trauma, pancreatitis, infection, and pancreatic cancer are examples of such disorders. Diabetes typically develops when the pancreas sustains considerable damage, although diabetes can also be connected to small, damaged pancreatic areas caused by adenocarcinomas. In addition, some illnesses can damage β-cells and interfere with insulin release, including as hemochromatosis, cystic fibrosis, and fibrocalculous pancreatitis [24].

Endocrinopathies :-

Diabetes can result from hormone excesses that counteract the effects of insulin. Diabetes can be brought on by conditions like acromegaly, which is caused by an excess of growth hormone; glucagonoma, which is caused by an excess of glucagon; pheochromocytoma, which is caused by an excess of epinephrine; and Cushing's syndrome, which is caused by an excess of cortisol. In fact, diabetes can be made worse, particularly in people who already have defects in their insulin secretion. Hypokalemia can be brought on by diseases such somatostatinomas and aldosteronomas, which further aids in the onset and advancement of diabetes in those who are afflicted [23].

Anti-insulin receptor antibody-related diabetes :-

Diabetes can result from antibodies that block the insulin receptor's ability to bind insulin. These antibodies may act as insulin agonists in specific situations, resulting in hypoglycemia rather than hyperglycemia. Antibodies that target the insulin receptor may be present in people with systemic lupus erythematosus and other autoimmune diseases. People who have this illness frequently have Acanthosis nigricans [25].

Infection :-

Certain viruses have been connected to the development of diabetes and the degeneration of beta cells. These viruses include adenovirus, cytomegalovirus, congenital rubella, mumps, and cox-sackievirus B. In people with genetic predispositions or markers linked to type 1 diabetes, their contribution to the development of diabetes is particularly noteworthy. These viruses have the potential to cause an immunological reaction in vulnerable people, which can result in beta-cell damage and the onset of diabetes [26].

EPIDEMIOLOGY :-

According to estimates, 366 million individuals had diabetes mellitus in 2011; by 2030, that number will have increased to 552 million.Every nation is seeing an increase in the number of persons with type 2 diabetes, with 80%

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1834-1844 www.ijprajournal.com ISSN: 2456-4494

of those affected residing in low- and middle-income nations. In 2011, 4.6 million people died from DM [27]. It is projected that by 2030, 439 million individuals would have type 2 diabetes [28]. After asthma, Type 1 diabetes is the second most common chronic childhood condition in the US, with a reported prevalence rate of 1.7 children per 1,000 [29]. More than 130,000 children in the US alone are thought to have Type 1 diabetes, with 13,000 new cases being identified each year [30]. The incidence of diabetes mellitus in adults, of which type 2 DM is becoming more common, is expected to rise over the next two decades. A large portion of this growth is expected to take place in emerging nations, where the majority of patients are between the ages of 45 and 64 [31].

PATHOPHYSIOLOGY :-

Type 1 DM :-

The pancreas's incapacity to secrete enough insulin to meet the body's metabolic needs appears to be the root cause of type 1 diabetes. During this process, the body gradually loses insulin, one of the main anabolic hormones, as β-cells gradually die off. It takes about 90% of the functional β-cell mass to be eliminated before obvious glucose intolerance manifests [32].The low-insulin, fasting, catabolic state and the high-insulin, anabolic state that occurs right after a meal are regularly alternated in the normal metabolic state. This promotes the storage of energy in the form of adipose tissue, protein, and glycogen for usage now or in the future. But in Type 1 diabetes, this insulin deficiency results in less glucose entering cells, which causes stored substrates to be released. In the lack of sufficient glucose in the cells, energy is obtained through lipolysis, glycogenolysis, and proteolysis. Serum cholesterol, free fatty acids, and triglycerides rise as a result of fat breakdown, whereas the catabolic state is brought on by an excessive usage of protein for cell energy. As a result, people with Type 1 diabetes are constantly in a catabolic, low-insulin state [33].

Type 2 DM :-

Insulin resistance, decreased insulin production, and ultimately pancreatic beta-cell failure cause insulin insensitivity, [34,35]which in turn reduces glucose transport into the liver, muscle cells, and fat cells. Hyperglycemia increases the breakdown of fat. Recently, the pathophysiology of type 2 DM has been linked to impaired alpha-cell function [36].

Hepatic glucose and glucagon levels that increase during fasting are not controlled by a meal because of this malfunction. Insufficient insulin levels and elevated insulin resistance lead to hyperglycemia. Insulin release and, in the case of GLP-1, glucagon suppression are both mediated by the gut's incretins. GLP-1 is a potentially useful therapeutic alternative since its insulinotropic effects are maintained in individuals with type 2 diabetes, despite the fact that GIP activity is compromised.DPP-IV, however, quickly deactivates GLP-1 in vivo, just like GIP does. [36]

Most people with type 2 diabetes have central visceral adiposity and are obese. As a result, adipose tissue is essential to the pathophysiology of type 2 diabetes. Two recently proposed theories, including the ectopic fat storage syndrome (deposition of triglycerides in muscle, liver, and pancreatic cells) and the portal/visceral hypothesis, which plays a major role in high non-esterified fatty acid concentrations, are utilized to explain this link. In the upcoming ten years, these two theories will serve as the foundation for research on the relationship between insulin resistance and beta-cell malfunction in type 2 diabetes, as well as between our obesogenic environment and the risk of developing the disease. [36]

CAUSES :-

ß cell gluco-receptor disruptions or abnormalities that cause them to react to elevated glucose concentrations or relative ß cell insufficiency. Either way, there is a reduction in insulin secretion, which could lead to ß cell failure [37]. The idea that microvascular illness causes cerebral hypoxia and that hyperglycemia directly affects neuronal metabolism [38].

Peripheral tissues' decreased sensitivity to insulin is caused by "down regulation" of insulin receptors and a decrease in their quantity. There are many hypersensitive and hyperinsulinemic people with normal glycemic levels who also have dyslipidemia, hyperuriemia, and abdominal fat. Relative insulin resistance exists as a result, especially in the liver, muscles, and fat. There is evidence linking hyperinsulinemia to angiopathy [39].

Obesity and excess levels of the hormones glucagon and hyperglycemia lead to a relative lack of insulin, which leads the ß cells to lag behind. Nitric oxide metabolism anomalies have been linked to altered perineural blood flow and nerve injury in two ideas [37].

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1834-1844 www.ijprajournal.com ISSN: 2456-4494

An excess of the hormones glucagon, hyperglycemia, and fat results in a relative lack of insulin, which leads the ß cells to lag behind. Abnormalities in nitric oxide metabolism have been linked to nerve injury and altered perineural blood flow in two theories [39].

Protein kinase C, advanced glycation-end products, oxidative stress, and the polyol pathway are the main topics of current research on diabetic neuropathy [38].

DIAGNOSIS :-

For Type 1 DM :-

Children suspected of having diabetes can be categorized into three groups: 1) those with a history of diabetes-like symptoms (e.g., polyuria, polydypsia, failure to gain weight, weight loss, enuresis, lethargy, or fatigue); 2) those with transient or persistent glycosuria; and 3) those with diabetic ketoacidosis (DKA) with or without coma. The presence of hyperglycemia in conjunction with glycosuria, either with or without ketonuria, and the absence of other metabolic diseases that impair the metabolism of carbohydrates are necessary for diagnosis in all cases. Type 1 diabetes can be diagnosed by combining the presence of classic symptoms with either a fasting plasma glucose (FPG) concentration of >126 mg/dL or a random plasma glucose concentration of >200 mg/dLAutoantibodies to insulin or islet cell autoantibodies mustbe measured in order to confirm that the diabetes is Type 1. Because of its high cost and difficulty of availability, the oral glucose tolerance test is not frequently used to diagnose paediatric patients. It is currently not advised to assess HbA1 C in order to diagnose Type 1 diabetes [40].

For Type 2 DM :-

Approximately 25% of individuals with type 2 diabetes already have microvascular problems at diagnosis, indicating that the disease has been present for longer than five years [41]. It is still based on the World Health Organization's (WHO) National Diabetic Group Criteria of 2006 or the American Diabetic Association's (ADA) 1997 guidelines, which call for a single elevated glucose reading with symptoms (weight loss, polyuria, polydipsia, and polyphagia) or two higher values of either fasting plasma glucose (FPG) ≥7.0 mmol/L (126 mg/dL) or an oral glucose tolerance test (OGTT) with a plasma glucose level of ≥11.1 mmol/L (200 mg/dL) two hours after the oral dose [42]. There is no clear HbA1c threshold at which normalcy stops and diabetes mellitus commences, much like with the glucose-based testing. [43] .The IEC decided to suggest a cut-off point for DM diagnosis that prioritises specificity, stating that this struck a balance between the minimal clinical repercussions of postponing the diagnosis in a patient with a HbA1c level less than 6.5% and the stigma and expense of incorrectly classifying people as diabetic [44].

MANAGEMENT OF DIABETES MELLITUS :-

The major goal of primary prevention is to stop diabetes from developing in the general population or in those who are vulnerable. Being physically active on a regular basis is crucial for managing and preventing type 2 diabetes. Increased physical activity has been linked to a lower incidence of type 2 diabetes, regardless of other risk variables, according to prospective cohort studies.[45,46,47]. The idea that changing one's lifestyle can avoid most cases of type 2 diabetes. A medical nutrition examination and lifestyle suggestions based on functional and physical abilities should be given to patients with type 2 diabetes [48].

Since most individuals with type 2 diabetes are overweight and frequently have other metabolic conditions associated with the insulin resistance syndrome, the main goals of dietary and lifestyle modifications areweightloss, improved glycemic control, and decreased risk of coronary heart disease (CHD), which is responsible for 70% to 80% of deaths among diabetics [49]. While food and lifestyle changes are thought to be the cornerstone for the treatment and maintenance of type 2 diabetes, insulin replacement therapy is the cornerstone for individuals with type 1 diabetes. In type 2 diabetes, insulin is also crucial when diet, exercise, weight loss, and oral medicines are insufficient to regulate blood glucose levels. In the management of type 2 diabetes, oral hypoglycemic medications are also helpful.Dietary and lifestyle strategies aim to lower weight, improve glycemic control, and lower the risk of cardiovascular complications, which account for 70% to 80% of deaths among people with diabetes25. Their primary objective is to restore normal metabolic disorders, such as insulin resistance and insufficient insulin secretion from the pancreas [50].

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1834-1844 www.ijprajournal.com ISSN: 2456-4494

TREATMENT :-

Insulin Therapy :-

Managing a patient with Type 1 aims to minimize the risk of long-term complications, minimize episodes of hyperglycemia and hypoglycemia, and restore normal growth. Delivery of insulin in amounts sufficient to fulfill metabolic needs, blood glucose monitoring, the creation and maintenance of suitable dietary programs, and getting enough exercise are the means by which these objectives are met. Hospitalization for a brief period of time is frequently necessary for the initial management of a newly diagnosed child with Type 1 diabetes in order to treat DKA. This includes closely monitoring blood glucose levels, administering insulin and glucose intravenously, and managing hydration and electrolyte balances. The patient must get education regarding insulin delivery, blood glucose monitoring, hypoglycemia and hyperglycemia symptoms, therapy, and early nutritional interventions throughout this hospital stay [51].

The goal of insulin therapy should be to emulate nature, which is incredibly effective in preventing hypoglycemia in between meals and reducing postprandial hyperglycemia. [52]. The location of insulin injection administration, which can be administered intramuscularly or intravenously, is equally crucial for the improved and secure action of insulin. Human, cow, and pork insulin are among the various forms of insulin that are accessible. Adverse effects and complications are not exclusive to insulin therapy. When an incorrect insulin dosage is administered and meals and insulin injections are not coordinated, the most significant side effects include weight gain and hypoglycemia [53,54].

Regular insulin has a 50–60 minute beginning of action and is a short-acting insulin[55]. It is a colorless, transparent fluid that can be injected intramuscularly, subcutaneously, or intravenously. Human insulin aspart (NovoLog) and insulin lispro (Humalog) are both fast-acting insulin analogs that start working 15 to 30 minutes after injection [55]. Because their quick onset, these agents can be administered right before meals rather than 20 to 45 minutes beforehand, as normal insulin requires. They are transparent, colorless solutions that can be injected intravenously, intramuscularly, or subcutaneously much like ordinary insulin. This stands in stark contrast to the fact that all other insulin preparations are suspensions [56].

HypoglycemicAgent :-

1.Biguanides for the management of T2DM :-

Metformin, a biguanide drug, has been the first-line treatment for lowering blood sugar in people with type 2 diabetes. This drug has FDA approval. By modifying the liver's sensitivity to insulin, this drug enhances glycemic control. However, there isn't much informationmostly from case reportsabout the negative effects of metformin. It's important to note that taking metformin can make it harder for a patient to sleep because it can cause unusual nightmares and, in rare cases, lactic acidosis. [57]

A 2008 study demonstrates that metformin also works by activating AMP-activated protein kinase, an enzyme involved in the production of hepatic gluconeogenic genes.[58]. Metformin should be taken cautiously in older diabetics with renal impairment due to the risk of developing lactic acidosis. In contrast to sulfonylureas, it has a low incidence of hypoglycemia [59].

2.Sulfonylureas for the management of T2DM :-

Second-line drugs called sulfonylureas are commonly used to treat T2DM in people who are not very fat. Since the introduction of tolbutamide in the 1950s, sulfonylureas have been used to treat type 2 diabetes. Acetohexamide, tolbutamide, chlorpropamide, and tolazamide are classified as first-generation medications, whereas glibenclamide, ligmepiride, gliclazide, glipizide, and gliquidone agents are classified as second-generation agents. The agents in the second generation are significantly more potent than those in the first, which is the primary difference between the two generations. Sulfonylureas are insulin secretagogues that increase the amount of insulin generated by pancreatic b-cells, lowering plasma glucose levels in the process [60-61]. Their mechanism of action involves directly blocking islet cells' ATP-sensitive K+ channels, which raises insulin production. [60].

3. Meglitinide derivatives for the management Of T2DM :-

Repaglinide and nateglinide are non-sulfonylurea secretagogues that, like sulfonylurea, stimulate the release of insulin from beta cells by acting on the ATP-dependent K-channel in the pancreatic beta cells, albeit with a different binding site. [62]. Cell membrane potential, which is dictated by the inverse relationship between extracellular glucose levels and potassium channels that are sensitive to adenosine triphosphate, is

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1834-1844 www.ijprajournal.com ISSN: 2456-4494

involved in the regulation of insulin generation by pancreatic b-cells. Extracellular glucose is transferred into the cell by glucose transporters 2 (GLUT2). As it enters the body, the cell breaks down glucose and uses and stores adenosine triphosphate (ATP) as energy. By blocking ATP-sensitive potassium channels, which depolarise B-cells, and opening calcium channels, which allow calcium to enter, they enhance the release of insulin. Increased calcium levels in cells promote the production of insulin [63,64].

4. Alpha glucosidase inhibitors (AGIs) for the management of T2DM:-

Although they have not been used extensively, acarbose, voglibose, and miglitol are probably safe and effective treatments for type 2 DM. These medications work well for postprandial hyperglycemia, and individuals with severe renal impairment should not use them. Due to the high incidence of side effects such flatulence and diarrhoea, their use is typically restricted.[65]. According to a study, the newest medication, voglibose, dramatically improves glucose tolerance in terms of both the number of patients who attain normoglycemia and the delayed course of the disease [66].

5. Dipeptidyl-Peptidase IV Inhibitors :-

By blocking dipeptidyl-peptidase-4 (DPP-4), a common enzyme that quickly deactivates both GLP-1 and GIP, dipeptidyl-peptidase IV inhibitors raise the active levels of both hormones, improving islet function and glycaemic management in type 2 diabetes [67]. A novel family of anti-diabetic medications called DPP-4 inhibitors works just as well as existing therapies. In individuals who are not well controlled with diet and exercise, they work well as monotherapy. They can also be used as an adjuvant therapy in conjunction with insulin, thiazolidinediones, and metformin. The DPP-4 inhibitors are weight neutral, have a minimal chance of causing hypoglycemia, and are well tolerated. They are somewhat pricey, though.[67] It is yet unknown how long-lasting the effects will be on beta-cell morphology and function as well as glycaemic control.[68,69].

HERBAL TREATMENT OF DIABETES MELLITUS :-

As traditional medicine research has advanced over the past few decades, plant-based medicines which are eco-friendly, bio-friendly, economical, and generally safehave emerged from the fringe to the mainstream. Several writers have reviewed the research on herbal anti-diabetic drugs, but Atta-ar-Rahman's review is the most instructive because it lists over 300 plant species that are recognized for their hypoglycemicqualities.Plants have been categorized in this review based on their botanical name, country of origin, parts used, and active agent type. Momordicacharantia, a member of the Cucurbitaceae family, is one such plant. [70]. The World Health Organization has listed 21,000 plants that are used medicinally worldwide. Out of these 2500 species, 150 are employed on a very considerable scale for commercial purposes in India. India is the largest producer of medicinal herbs and is termed the botanical garden of the world [71].

II. CONCLUSION :-

Diabetes mellitus type 1 is caused by the pancreas no longer producing significant amounts of the hormone insulin, usually due to autoimmune destruction of the insulin-producing beta cells of the pancreas. Diabetes mellitus type 2 is now thought to be caused by autoimmune attacks on the pancreas and/or insulin resistance. Although the pancreas of a person with type 2 diabetes may be producing normal or even abnormally large amounts of insulin, the main goal of diabetes management is to return carbohydrate metabolism to a normal level if possible. The primary objective of managing diabetes is to return the metabolism of carbohydrates as normal as possible. For those who have a complete insulin shortage, insulin replacement therapywhich is administered by injections or tabletsis necessary to accomplish this goal. Conversely, diet changes and exercise can help improve insulin resistance. Other objectives of diabetes care include preventing or treating the numerous problems that can arise from both the disease and its management. It is possible to make diabetes a patient's companion and enable them to live a happy life by managing their blood sugar levels.

ACKNOWLEDGEMENT:-

I have to say thanks to my guide Ms. Sucheta Pawar for her constructive suggestions, support and constant motivation.Appreciation is also extended to YSPM's, YTC SATARA for providing the necessary resources and support during the preparation of this review. Finally, we thank all the researchers whose valuable work has been cited and discussed in this article.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 2 Mar–Apr 2025, pp: 1834-1844 www.ijprajournal.com ISSN: 2456-4494

REFERENCE :-

[1]. A. Poznyak, A.V. Grechko, P. Poggio, V.A. Myasoedova, V. Alfieri, A.N. Orekhov, The diabetes mellitus–atherosclerosis connection: The role of lipid and glucose Metabolism and chronic inflammation, Int. J. Mol. Sci. 21.(5)(2020)1835, https://doi.org/10.3390/ijms21051835.

[2]. Ismail, M.Y., Clinical evaluation of antidiabetic activity of Trigonella seeds and Aegle marmelos Leaves, Worl Appl Scien J., 7(10): 1231-1234 (2009)

[3]. M.C. Rossi, A. Nicolucci, A. Ozzello, S. Gentile, A. Aglialoro, A. Chiambretti, F. Baccetti, F.M. Gentile, F. Romeo, G. Lucisano, Impact of severe and symptomatic hypoglycemia on quality of life and fear of hypoglycemia in type 1 and type 2 diabetes. Results of the Hypos-1 observational study, Nutr., Metab. Cardiovasc. Dis. 29 (7) (2019) 736–743, https://doi.org/10.1016/j.numecd.2019.04.009.

[4]. Wassmuth R, Lernmark A. The genetics of susceptibility to diabetes, ClinImmunol, Immunopathol. 1989; 53:358-399,

[5]. Atkinson MA, Eisenbarth GS. Type 1 diabetes new perspectives on disease pathogenesis and treatment, Lancet. 2001; 358:221-229.

[6]. WHO, Diabetes, 2019. N.A. ElSayed, G. Aleppo, V.R. Aroda, R.R. Bannuru, F.M. Brown, D. Bruemmer, B. S. Collins, J.L. Gaglia, M.E. Hilliard, D. Isaacs, E.L. Johnson, 2. Classification and diagnosis of diabetes: standards of care in diabetes—2023, Diabetes care 46 (Supplement_1) (2023) S19–S40.

[7]. Verge CF, Gianani R, Kawasaki E, Yu L, Pietropaolo M, Jackson RA et al., Predicting type I diabetes in first–Degree relatives using a combination of insulin, GAD, and ICA512bdc/IA-2autoantibodiesDiabetes. 1996;45:926-33.

[8]. American Diabetes Association, Diagnosis and Classification of diabetes mellitus, Diabetes Care, 2014, 1.

[9]. Kumar CR. Basic Pathology, Prism PVT. Limited Bangalore, 5th edition, 1992, 569-587.

[10]. Jun SK, Yoon YW. A new look at viruses in Type 1 Diabetes, Diabetes/Metabolism Research and Reviews.

[11]. Wassmuth R, Lernmark A. The genetics of susceptibility to diabetes, ClinImmunol, Immunopathol. 1989; 53:358-399,

[12]. Arora, S., Ojha, S.K., Vohora, D., Characterisation of Streptozotocin induced diabetes mellitus in Swiss Albino mice, Glo J of Pharmacol., 3(2): 81-84 (2009)

[13]. N.A. ElSayed, G. Aleppo, V.R. Aroda, R.R. Bannuru, F.M. Brown, D. Bruemmer, B. S. Collins, J.L. Gaglia, M.E. Hilliard, D. Isaacs, E.L. Johnson, 2. Classification anddiagnosis of diabetes: standards of care in diabetes—2023, Diabetes care 46 (Supplement_1) (2023) S19–S40.

[14]. S. Merger, R.D. Leslie, B.O. Boehm, The broad clinical phenotype of Type 1 diabetes at presentation, Diabetic Medicine 30 (2) (2013) 170–178.

[15]. A. Imagawa, T.J.EjHanafusa, Fulminant type 1 diabetes mellitus 53 (5) (2006) 577–584, https://doi.org/10.1507/endocrj.KR-72.

[16]. A. Imagawa, T.J.DmrHanafusa, Fulminant type 1 diabetes—an important subtype in East Asia, reviews 27 (8) (2011) 959–964, https://doi.org/10.1002/dmrr.1236

[17]. Lonardo, A., Nascimbeni, F., Mantovani, A. &Targher, G. Hypertension, diabetes, Atherosclerosis and NASH: Cause or consequence. J. Hepatol. 68, 335–352(2018).

[18]. Ross and Wilson. Anatomy and Pathophysiology in health and Illness, Churchill Livingstone Elsevier, 11thEdition, 2010, 227-229.

[19]. Harris MI. Undiagnosed NIDDM, clinical and public health issues, Diabetes Care. 1993; 16:642-52

[20]. Jun SK, Yoon YW. A new look at viruses in Type 1 Diabetes, Diabetes/Metabolism Research and Reviews. 2002; 19:8-31.

[21]. J.F. Plows, J.L. Stanley, P.N. Baker, C.M. Reynolds, M.H.J.Ijoms Vickers, The pathophysiology of gestational diabetes mellitus 19 (11) (2018) 3342, https://doi. Org/10.3390/ijms19113342.

[22]. C.C. Thomas, L.H. Philipson, Update on diabetes classification, Med. Clin. 99 (1) (2015) 1–16, https://doi.org/10.1016/j.mcna.2014.08.015.

[23]. A.D. Association, Diagnosis and classification of diabetes mellitus. Diabetes Care 2010; 33 (Suppl. 1): S62-

S69, Erratum in: Diabetes Care 33, 2010:e57.https://doi.Org/10.2337/dc10-S062.

[24]. A.A. Kazi, L. Blonde, Classification of diabetes mellitus, Clin. Lab. Med. 21 (1) (2001) 1–13, https://doi.org/10.1002/hep4.1105.

[25]. E.D. Rosenstein, S. Advani, R.E. Reitz, N. Kramer, The prevalence of insulin receptor antibodies in patients with systemic lupus erythematosus and related conditions, JCR: J. Clin. Rheumatol. 7 (6) (2001) 371–373, https://doi.org/10.1097/00124743-200112000-00004.

[26]. A.A. Kazi, L. Blonde, Classification of diabetes mellitus, Clin. Lab. Med. 21 (1) (2001) 1–13, https://doi.org/10.1002/hep4.1105

[27]. Global burden of diabetes. International Diabetes federation. Diabetic atlas Fifth edition 2011, Brussels. Available at http://www.idf.org/diabetesatlas. (Accessed 18th December 2011).

[28]. Chamnan P, Simmons RK, Forouhi NG, Luben R. Khaw Ky, Wareham NJ Et al. Incidence of type 2 diabetes using proposed HbA1c diagnostic criteria In the EPIC-Norflok cohort: Implication for preventive strategies. Available At http://care.diabetesjournal.org. (Accessed 19th December 2011).

[29]. Kaufman FR. Diabetes in children and ado-lescents: Areas of controversy. Med ClinNorth Am 1998;82:721-38.

[30]. Fenton CL, Clemons PM, Francis GL. How do the results of the Diabetes Control and complications Trial relate to the practice ofpediatrics: Who should have intensive man- agement? Pediatr Ann 1999;28:600-4.

[31]. GBD 2021 Diabetes Collaborators. Global, regional, and national burden ofdiabetes from 1990 to 2021, with projections of prevalence to 2050: a sys-tematic analysis for the Global Burden of Disease Study 2021. Lancet 402,203–234 (2023).

[32]. Plotnick L. Insulin-dependent diabetes mellitus. Pediatr Rev 1994;15:137-45.

[33]. Sperling MA. Aspects of the etiology, prediction, and prevention of insulin-dependent diabetes mellitus in childhood. Pediatr Clin North Am 1997;44:269-84.

[34]. Kahn CR. Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 1994 Aug;43(8):1066-1084.

[35]. Robertson RP. Antagonist: diabetes and insulin resistance–philosophy, science, and the multiplier hypothesis. J Lab Clin Med 1995 May;125(5):560-564, discussion 565.

[36]. Fujioka K. Pathophysiology of type 2 diabetes and the role of incretin hormones and beta-cell dysfunction. JAAPA 2007; suppl 3-8.

[37]. Alemu S, Dessie A, Seid E. Insulin-requiring diabetes in rural Ethiopia: should we reopen the case for malnutrition-related diabetes, Diabetologia. 2009; 52:1842-1845.

[38]. Wild S, Roglic G, Green A, Sicree R, King. Global prevalence of diabetes: Estimates for the year 2000 and projections for 2030, Diabetes Care. 2004; 27:1047-53.

[39]. Gupta OP, Joshi MH, Daves SK. Prevalence of Diabetes in India, Adv MetabDisord. 1978; 9:147-65.

[40]. The Expert Committee on the Diagnosis and classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 2001;24(S1):S5-S21.

[41]. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care 1992 Jul;15(7):815-819.

[42]. Cox EM, Elelman D. Test for screening and diagnosis of type 2 diabetes. Clin diabetes 2009;4(27):132-138 .

[43]. Cox EM, Elelman D. Test for screening and diagnosis of type 2 diabetes. Clin diabetes 2009;4(27):132-138

[44]. International Expert Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care 2009;32:1-8

[45]. Ross, R., Dagnone, D., Jones, P.J. Reduction in obesity and related co-morbid conditions after diet induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Int Med; 133: 92-103 (2000)

[46]. Helmrich, S.P., Ragland, D.R., Leung, R.W., Paffenbarger, R.S. Physical activity

and reduced occurrence of noninsulin-dependent diabetes mellitus. Eng J Med 325: 147-152 (1991)

[47]. Manson, J.E., Nathan, D.M., Krolewski, A.S. A prospective study of exercise and incidence of diabetes among U.S. male physicians. J Am Med Assoc 268: 63-67 (1992)

[48]. Chiniwala N, Jabbour S. Management of diabetes mellitus in the elderly. currOpin Endocrinol Diabetes Obes 2011 Apr;18(2):148-152

[49]. National Institutes of Health. Diabetes in America, 2nd edition, Bethesda,1995, MD: National institutes of Health,. (NIH Publication no. 95-1468.)

[50]. Kumar, P.J., Clark, M. Textbook of Clinical Medicine. 2002, Pub: Saunders (London), Page 1099-1121.

[51]. Lorenz RA. Modern Insulin Therapy for type 1 Diabetes Mellitus. Diabetes1999;26:917-29.

[52]. Ciofeta, M., Lalli, C., Del, S. P. Contribution of postprandial versus interprandial blood glucose to HbA1c in type I diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care. 22: 795-800 (1999)

[53]. Diabetes Control and Complications Trial Research Group. The effects of intensive treatment of Diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Eng J Med., 329: 977-986 (1993)

[54]. Yki-Jarvinen, H., Ryysy, L., Nikkilä, K., Tulokas, T.,Vanamo, R,, Heikkila, M. Comparison of bedtime insulin regimens in patients with type 2 diabetes mellitus: a randomized trial. Ann Intern Med; 130: 289-396 (1999)

[55]. Steil CF. Diabetes Mellitus. In: DipiroJT,talbert RL, Yee GC, Matzke GR, Wells BG posey LM, eds. Pharmacotherapy: A Patho-Physiologic Approach. Stamford: Appleton& Lange; 1999:1219-43.

[56]. Drug Facts and Comparisons. Killion KH,burnham TH, Wickersham RM, Novak KKharmon LD, McCarron SM, et al, eds. St.Louis, MO: Facts and Comparisons, 2001.

[57]. Susilawati E, Levita J, Susilawati Y, Sumiwi SA. Review of the case reports on metformin, sulfonylurea, and thiazolidinedione therapies in type 2 diabetes mellitus patients. Med Sci (Basel). (2023) 11:50. Doi: 10.3390/medsci11030050

[58]. Kim YD, Park KG, Lee YS, Park YY, Kim DK, Nedumaran B, et al. metformin inhibits hepatic gluconeogenesis through AMP-activated protein kinase-dependent regulation of the orphan nuclear receptor SHP. Diabetes 2008 Feb;57(2):306-314.

[59]. Collier CA, Bruce CR, Smith AC, Lopaschuk G, Dyck DJ. Metformin counters the insulin-induced suppression of fatty acid oxidation and stiimulation of triacyglycerol storage in rodents skeletal muscle. Am J PhysiolendocrinolMetab 2006;219(1):182-189 .

[60]. Sola D, Rossi L, Schianca GP, Maffioli P, Bigliocca M, Mella R, et al. and their use in clinical practice. Arch Med Sci. (2015) 11:840–8.Doi: 10.5114/aoms.2015.53304

[61]. Kalra S, Bahendeka S, Sahay R, Ghosh S, Md F, Orabi A, et al. Consensus recommendations on sulfonylurea and sulfonylurea combinations in the managementof type 2 diabetes mellitus – international task force. Indian J Endocrinol Metab. (2018)22:132–57. Doi: 10.4103/ijem.IJEM_556_17

[62]. Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, et al. stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998 Mar;47(3):345-351.

[63]. 63) Keegan MT. Endocrine pharmacology. PharmacolPhysiolanesthesia: Elsevier;.(2019) p:708–31. Doi: 10.1016/B978-0-323-48110-6.00036-3

[64]. Fridlyand LE, Jacobson DA, Philipson LH. Ion channels and regulation of insulin secretion in human b-cells: a computational systems analysis. Islets. (2013) 5:1–15. doi: 10.4161/isl.24166

[65]. Chiniwala N, Jabbour S. Management of diabetes mellitus in the elderly. currOpin Endocrinol Diabetes Obes 2011 Apr;18(2):148-152.

[66]. Kawamori R, Tajima N, Iwamoto Y, Kashiwagi A, Shimamoto K, Kaku K; voglibose Ph-3 Study Group. Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in

Japanese individuals with impaired glucose tolerance. Lancet 2009 May;373(9675):1607-1614.

[67]. Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin 2007 Apr;23(4):919-931

[68]. Pratley RE, Salsali A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. Curr Med Res Opin 2007 Apr;23(4):919-931.

[69]. Barnett A. DPP-4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 2006 Nov;60(11):1454-1470.

[70]. Rahman, A.R., Zaman, K. Medicinal Plants with hypoglycaemic activity. J ethnopharmacol 26: 1-55 (1989)

[71]. Modak, M., Dixit, P., Londhe, J. Devasagayam. Indian herbs and herbal drugs used for the treatment of diabetes. J Clin BiochemNutr 40: 163-73 (2007).